Severe Malaria Clinical Trial
Official title:
Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections.
Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. At each replicating cycle within erythrocytes, a proportion of asexual parasites converts into non-replicative sexual stages, which are the only forms able to infect mosquitos. The rate at which sexual stages are produced, is known as basal sexual conversion rate. Changes in the host immune and metabolic environment associated with the development of malaria disease, such as depletion of lysophosphatidylcholine in plasma, have been associated with increased sexual conversion rates in vitro. It is hypothesised that immune and metabolite factors that are altered during malaria infection induce sexual conversion in Plasmodium falciparum parasites. In this project, a new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections. The aim is to identify immune factors and metabolites that induce sexual conversion using in-house developed sexual conversion assays, and experimental mosquito infections. Finally, transcriptional mechanisms are explored driving parasite sexual conversion in the host environment during disease using single-cell RNA-sequencing approaches. This research will provide essential knowledge on the factors that affect sexual conversion in the host and potentially inform novel strategies to interrupt transmission. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01955382 -
Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
|
Phase 2 | |
| Not yet recruiting |
NCT01122134 -
Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment
|
N/A | |
| Recruiting |
NCT04675931 -
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
|
Phase 2 | |
| Recruiting |
NCT05685875 -
Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon
|
||
| Completed |
NCT02451904 -
Severe and Cerebral Malaria Investigated Through Host Metabolomics
|
||
| Completed |
NCT04037332 -
Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
|
||
| Completed |
NCT00341003 -
Severe Malaria and Anti-malarial Drug Resistance in Cambodia
|
N/A | |
| Completed |
NCT01255215 -
Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT05140278 -
Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate
|
Phase 2 | |
| Recruiting |
NCT05711485 -
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
|
N/A | |
| Completed |
NCT04473768 -
Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
|
||
| Completed |
NCT04176029 -
Lung Ultrasound in Children With Severe Malaria
|
||
| Recruiting |
NCT04251351 -
Effect of Paracetamol on Kidney Function in Severe Malaria
|
Phase 3 | |
| Completed |
NCT00342043 -
Examination of Protective Factors Against Severe Malaria
|
N/A | |
| Completed |
NCT04516317 -
Very Severe Malaria Treated by Intravenous Artesunate
|
||
| Completed |
NCT01828333 -
Malaria Treatment With Injectable ArteSunate
|
N/A |